Table 1. Characteristics of studies included in systematic review.
|
Study population |
||||||||
|---|---|---|---|---|---|---|---|---|
| First author | Year | Country | CRC (no. of patients) | Control (no. of patients) | Age (mean±s.d./(range)), years | Gender male: female | Specimen | |
| Ng | 2009 | China | 130 | 75 | CRC | 71 (42–91) | 68 : 62 | Plasma |
| Control | 69 (45–85) | 39 : 36 | ||||||
| Huang | 2010 | China | 100 | 59 | CRC | 61±11 | 51 : 49 | Plasma |
| Control | 58±12 | 31 : 28 | ||||||
| Pu | 2010 | China | 103 | 37 | CRC | 58 (39–84) | 66 : 37 | Plasma |
| Control | 32 (17–77) | 19 : 18 | ||||||
| Kanaan | 2012 | USA | 50 | 50 | CRC | 60±11 | 21 : 29 | Plasma |
| Control | 61±9 | 21 : 29 | ||||||
| Wang Q | 2012 | China | 100 | 68 | CRC | 61 (21–84) | 50 : 50 | Plasma |
| Control | 57 (36–85) | 35 : 33 | ||||||
| Wang B | 2012 | China | 32 | 39 | CRC | 63 (45–80) | 17 : 15 | Serum |
| Control | 46 | 30 : 9 | ||||||
| Ahmed | 2012 | USA | 10 | 5 | CRC | — | — | Plasma |
| Control | — | — | ||||||
| Kanaan | 2013 | USA | 45 | 26 | CRC | 64 | 28 : 17 | Plasma |
| Control | 60±11 | 11 : 15 | ||||||
| Zhang G | 2012 | China | 78 | 86 | CRC | 61.4±13.6 | 43 : 35 | Plasma |
| Control | 60.3±11.8 | 53 : 33 | ||||||
| Luo | 2013 | Germany | 130 | 244 | CRC | 67.55 | 70 : 60 | Plasma |
| Control | 61.93 | 105 : 139 | ||||||
| Giraldez | 2013 | Spain | 63 | 73 | CRC | — | — | Plasma |
| Control | 61.35 | 37 : 36 | ||||||
| Brunet Vega | 2013 | Spain | 30 | 26 | CRC | 68.1±11 | 18 : 12 | Serum |
| Control | 64.1±7.4 | 13 : 13 | ||||||
| Liu | 2013 | China | 200 | 80 | CRC | 57.09 (20–89) | 126 : : 74 | Serum |
| Control | 57.71 (28–89) | 42 : 38 | ||||||
| Yu H | 2013 | China | 30 | 30 | CRC | — | — | Serum |
| Control | — | — | ||||||
| Toiyama | 2013 | USA | 186 | 53 | CRC | 67.5±7.5 | 106 : 80 | Serum |
| Control | 64±12.9 | 27 : 26 | ||||||
| Hofsli | 2013 | Norway | 70 | 20 | CRC | 70.5 | 32 : 38 | Serum |
| Control | ⩾50 | 10 : 10 | ||||||
| Perilli | 2014 | Italy | 20 | 10 | CRC | — | — | Plasma |
| Control | — | — | ||||||
| Basati | 2014 | Iran | 40 | 40 | CRC | 55.35±10.13 | 21 : 19 | Serum |
| Control | 55.00±10.35 | 22 : 18 | ||||||
| Zheng | 2014 | China | 307 | 226 | CRC | 57.68 | 180 : 127 | Serum |
| Control | 53.15 | 128 : 98 | ||||||
| Du | 2014 | China | 49 | 49 | CRC | — | — | Plasma |
| Control | — | — | ||||||
| Xu | 2014 | China | 94 | 46 | CRC | 64.9 | 54 : 40 | Plasma |
| Control | 65.8 | 22 : 24 | ||||||
| Zanutto | 2014 | Italy | 65 | 70 | CRC | — | — | Plasma |
| Control | — | — | ||||||
| Chen | 2015 | China | 100 | 79 | CRC | 58.91 | 60 : 40 | Plasma |
| Control | 60.20 | 44 : 35 | ||||||
| Ramzy | 2015 | Egypt | 25 | 10 | CRC | — | — | Serum |
| Control | — | — | ||||||
| Ho | 2015 | USA | 11 | 10 | CRC | 68.0 | 8 : 3 | Serum |
| Control | 54.5 | 4 : 6 | ||||||
| Li J | 2015 | China | 175 | 130 | CRC | 58.7 | 113 : 62 | Serum |
| Control | 54.1 | 70 : 50 | ||||||
| Li L | 2015 | China | 200 | 400 | CRC | 66.3±11.8 | 135 : 65 | Plasma |
| Control | 65.5±10.8 | 283 : : 117 | ||||||
| Fang | 2015 | China | 111 | 130 | CRC | 60 | 59 : 52 | Plasma |
| Control | — | — | ||||||
| Basati | 2015 | Iran | 55 | 55 | CRC | 58.52±10 | 30 : 25 | Serum |
| Control | 57.87±10.15 | 31 : 24 | ||||||
| Ghanbari | 2015 | Iran | 61 | 24 | CRC | 64.13±8.67 | 34 : 27 | Plasma |
| Control | 61.96±8.67 | 14 : 10 | ||||||
| Wang S | 2015 | China | 124 | 117 | CRC | 64 | 54 : 70 | Plasma |
| Control | 43 | 65 : 52 | ||||||
| Wang W | 2016 | China | 268 | 102 | CRC | 58 (49–66) | 151 : 117 | Serum |
| Control | 56 (48–66) | — | ||||||
| Sun | 2016 | USA | 227 | 57 | CRC | 55±7.8 | 119 : 108 | Plasma |
| Control | 54±6.3 | 27 : 30 | ||||||
| Yu J | 2016 | China | 165 | 30 | CRC | 60.7±11.6 | 78 : 87 | Serum |
| Control | 59.4±14.5 | 15 : 15 | ||||||
Abbreviation: CRC, colorectal cancer.